Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Upon entering the agreement, Aspire purchased $1 million in common stock, and may purchase up to $14 million more at Biocept's discretion.
The partners will use Biocept's liquid biopsy systems to detect estrogen receptor gene mutations that could help guide treatment for women with breast cancer.
Under the agreements, members of Fortified Provider Network and Three Rivers Provider Network will now have access to Biocept's liquid biopsy tests.
It accessioned 482 commercial cases during the quarter, nearly five times the 96 commercial cases for the third quarter of 2014.
Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.
The agreements with the PPOs bring the total number of Americans with covered access to Biocept's tests to about 31 million.
An increase in testing volume drove revenue growth in the quarter, though net loss also increased due to expenses associated with marketing and performing tests.
The partners will explore the use of Biocept's liquid biopsy technology to identify and detect biomarkers in ER-positive breast cancer patients.
Researchers and commercial vendors highlighted new data and clinical utility, but also discussed challenges in validating and establishing liquid biopsy diagnostics.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.